Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Anumana is expanding beyond diagnostic ECG-AI technology into perioperative and acute cardiac care and has welcomed Boston ...

Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...